Human HGFR/c-MET Antibody
Human HGFR/c-MET Antibody Summary
Glu25-Thr932
Accession # P08581
Complete Your Research
Complete Your Experiment
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of HGF R/c‑MET in MDA‑MB‑231 Human Cell Line by Flow Cytometry. MDA-MB-231 human breast cancer cell line was stained with Human HGF R/c-MET Monoclonal Antibody (Catalog # MAB3582, filled histogram) or isotype control antibody (Catalog # MAB002, open histogram), followed by Allophycocyanin-conjugated Anti-Mouse IgG F(ab')2Secondary Antibody (Catalog # F0101B).
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: HGFR/c-MET
HGF R, also known as Met (from N-methyl-N’-nitro-N-nitrosoguanidine induced), is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGF R is synthesized as a single chain precursor which undergoes cotranslational proteolytic cleavage. This generates a mature HGF R that is a disulfide-linked dimer composed of a 50 kDa extracellular alpha chain and a 145 kDa transmembrane beta chain (1, 2). The extracellular domain (ECD) contains a seven bladed beta -propeller sema domain, a cysteine-rich PSI/MRS, and four Ig-like E-set domains, while the cytoplasmic region includes the tyrosine kinase domain (3, 4). Proteolysis and alternate splicing generate additional forms of human HGF R which either lack of the kinase domain, consist of secreted extracellular domains, or are deficient in proteolytic separation of the alpha and beta chains (5-7). The sema domain, which is formed by both the alpha and beta chains of HGF R, mediates both ligand binding and receptor dimerization (3, 8). Ligand-induced tyrosine phosphorylation in the cytoplasmic region activates the kinase domain and provides docking sites for multiple SH2-containing molecules (9, 10). HGF stimulation induces HGF R downregulation via internalization and proteasome-dependent degradation (11). In the absence of ligand, HGF R forms non-covalent complexes with a variety of membrane proteins including CD44v6, CD151, EGF R, Fas, Integrin alpha 6/ beta 4, Plexins B1, 2, 3, and MSP R/Ron (12-19). Ligation of one complex component triggers activation of the other, followed by cooperative signaling effects (12-19). Formation of some of these heteromeric complexes is a requirement for epithelial cell morphogenesis and tumor cell invasion (12, 16, 17). Paracrine induction of epithelial cell scattering and branching tubulogenesis results from the stimulation of HGF R on undifferentiated epithelium by HGF released from neighboring mesenchymal cells (20). Genetic polymorphisms, chromosomal translocation, over-expression, and additional splicing and proteolytic cleavage of HGF R have been described in a wide range of cancers (1). Within the ECD, human HGF R shares 86-88% amino acid sequence identity with canine, mouse, and rat HGF R.
- Birchmeier, C. et al. (2003) Nat. Rev. Mol. Cell Biol. 4:915.
- Corso, S. et al. (2005) Trends Mol. Med. 11:284.
- Gherardi, E. et al. (2003) Proc. Natl. Acad. Sci. USA 100:12039.
- Park, M. et al. (1987) Proc. Natl. Acad. Sci. USA 84:6379.
- Crepaldi, T. et al. (1994) J. Biol. Chem. 269:1750.
- Prat, M. et al. (1991) Mol. Cell. Biol. 12:5954.
- Rodrigues, G.A. et al. (1991) Mol. Cell. Biol. 11:2962.
- Kong-Beltran, M. et al. (2004) Cancer Cell 6:75.
- Naldini, L. et al. (1991) Mol. Cell. Biol. 11:1793.
- Ponzetto, C. et al. (1994) Cell 77:261.
- Jeffers, M. et al. (1997) Mol. Cell. Biol. 17:799.
- Orian-Rousseau, V. et al. (2002) Genes Dev. 16:3074.
- Klosek, S.K. et al. (2005) Biochem. Biophys. Res. Commun. 336:408.
- Jo, M. et al. (2000) J. Biol. Chem. 275:8806.
- Wang, X. et al. (2002) Mol. Cell 9:411.
- Trusolino, L. et al. (2001) Cell 107:643.
- Giordano, S. et al. (2002) Nat. Cell Biol. 4:720.
- Conrotto, P. et al. (2004) Oncogene 23:5131.
- Follenzi, A. et al. (2000) Oncogene 19:3041.
- Sonnenberg, E. et al. (1993) J. Cell Biol. 123:223.
Product Datasheets
Citations for Human HGFR/c-MET Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
10
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
Adipose stem cell niche reprograms the colorectal cancer stem cell metastatic machinery
Authors: S Di Franco, P Bianca, DS Sardina, A Turdo, M Gaggianesi, V Veschi, A Nicotra, LR Mangiapane, M Lo Iacono, I Pillitteri, S van Hooff, F Martorana, G Motta, E Gulotta, VL Lentini, E Martorana, ME Fiori, S Vieni, MR Bongiorno, G Giannone, D Giuffrida, L Memeo, L Colarossi, M Mare, P Vigneri, M Todaro, R De Maria, JP Medema, G Stassi
Nature Communications, 2021;12(1):5006.
Species: Human
Sample Types: Whole Tissue
Applications: ICC -
Aberrant Expression of and Cell Death Induction by Engagement of the MHC-II Chaperone CD74 in Anaplastic Large Cell Lymphoma (ALCL)
Authors: KD Wurster, M Costanza, S Kreher, S Glaser, B Lamprecht, N Schleussne, I Anagnostop, M Hummel, K Jöhrens, H Stein, A Molina, A Diepstra, B Gillissen, K Köchert, R Siebert, O Merkel, L Kenner, M Janz, S Mathas
Cancers, 2021;13(19):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
c-Met-Specific Chimeric Antigen Receptor T Cells Demonstrate Anti-Tumor Effect in c-Met Positive Gastric Cancer
Authors: CH Kang, Y Kim, DY Lee, SU Choi, HK Lee, CH Park
Cancers, 2021;13(22):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
ERBB3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to ERBB3 targeting in glioblastoma
Authors: F De Bacco, F Orzan, J Erriquez, E Casanova, L Barault, R Albano, A D'Ambrosio, V Bigatto, G Reato, M Patanè, B Pollo, G Kuesters, C Dell'Aglio, L Casorzo, S Pellegatta, G Finocchiar, PM Comoglio, C Boccaccio
Cell Reports, 2021;36(4):109455.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
Authors: T Khan, AM Seddon, AG Dalgleish, S Khelwatty, N Ioannou, S Mudan, H Modjtahedi
Oncol Rep, 2020;0(0):.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma
Authors: BW Stringer, BW Day, RCJ D'Souza, PR Jamieson, KS Ensbey, ZC Bruce, YC Lim, K Goasdoué, C Offenhäuse, S Akgül, S Allan, T Robertson, P Lucas, G Tollesson, S Campbell, C Winter, H Do, A Dobrovic, PL Inglis, RL Jeffree, TG Johns, AW Boyd
Sci Rep, 2019;9(1):4902.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Necrotic cell-derived high mobility group box 1 attracts antigen-presenting cells but inhibits hepatocyte growth factor-mediated tropism of mesenchymal stem cells for apoptotic cell death.
Authors: Vogel S, Borger V, Peters C, Forster M, Liebfried P, Metzger K, Meisel R, Daubener W, Trapp T, Fischer J, Gawaz M, Sorg R
Cell Death Differ, 2015;22(7):1219-30.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
beta1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma.
Authors: Carbonell W, DeLay M, Jahangiri A, Park C, Aghi M
Cancer Res, 2013;73(10):3145-54.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Down-regulation of the met receptor tyrosine kinase by presenilin-dependent regulated intramembrane proteolysis.
Authors: Foveau B, Ancot F, Leroy C, Petrelli A, Reiss K, Vingtdeux V, Giordano S, Fafeur V, Tulasne D
Mol. Biol. Cell, 2009;20(9):2495-507.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry -
Resistance of acute myeloid leukemic cells to the triterpenoid CDDO-Imidazolide is associated with low caspase-8 and FADD levels.
Authors: Riccioni R, Senese M, Diverio D, Riti V, Mariani G, Boe A, LoCoco F, Foa R, Peschle C, Sporn M, Testa U
Leuk. Res., 2008;32(8):1244-58.
Species: Human
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsIsotype Controls
Reconstitution Buffers
Secondary Antibodies
Reviews for Human HGFR/c-MET Antibody
Average Rating: 4 (Based on 4 Reviews)
Have you used Human HGFR/c-MET Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Detection of human HGFR/c-MET on epidermoid carcinoma cell line A-431. A-431 cells were treated with 100 nM of the human HGFR/c-MET antibody (catalog # MAB3582) or mouse IgG1 isotype control, followed by a secondary antibody goat a-mouse IgG Fc APC. Isotype control (RED), human HGFR/c-MET antibody (BLUE).
Antibody was printed on custom arrays and incubated with fluorescently labeled human EDTA plasma
